{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:02:04Z","timestamp":1794002524611,"version":"4.8.0"},"reference-count":257,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T00:00:00Z","timestamp":1754611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Diabetic kidney disease (DKD) has emerged as the leading cause of chronic kidney disease (CKD) worldwide, surpassing primary glomerular disorders in prevalence. Despite recent therapeutic advances, current treatment strategies primarily alleviate symptoms rather than address the underlying pathogenic mechanisms, highlighting an urgent need for targeted, mechanism-based interventions. The pathogenesis of DKD involves a complex interplay of metabolic, hemodynamic, inflammatory, oxidative, and fibrotic pathways. Chronic hyperglycemia initiates a cascade of molecular events\u2014including the accumulation of advanced glycation end products (AGEs), activation of the polyol pathway, enhanced protein kinase C (PKC) signaling, and mitochondrial dysfunction\u2014culminating in glomerular hyperfiltration, podocyte injury, and progressive glomerular and tubulointerstitial fibrosis. In addition to these classical mechanisms, emerging processes such as ferroptosis (iron-dependent cell death), impaired autophagy, gut microbiota dysbiosis, and epigenetic alterations offer promising therapeutic targets. Current DKD management integrates lifestyle modifications with four cornerstone pharmacologic classes: renin\u2013angiotensin\u2013aldosterone system inhibitors (RAASi), sodium\u2013glucose co-transporter 2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1 RAs), and mineralocorticoid receptor antagonists (MRAs). Notably, evidence from clinical trials suggests that simultaneous modulation of multiple pathogenic pathways provides superior cardiorenal protection compared to monotherapy. Investigational therapies\u2014including endothelin receptor antagonists (ERAs), nuclear factor erythroid 2\u2013related factor 2 (Nrf2) activators, and gut microbiota modulators\u2014are under active evaluation. Additionally, Traditional Chinese Medicine (TCM) formulations have demonstrated albuminuria-lowering effects in clinical studies. Future research should prioritize biomarker-driven precision medicine approaches, enabling individualized therapy selection and development of agents that concurrently target ferroptosis and inflammation. Given the multifaceted pathophysiology of DKD, optimal management will require multimodal, patient-tailored regimens that address hyperglycemia, hypertension, inflammation, and fibrosis to effectively slow or halt disease progression.<\/jats:p>","DOI":"10.3389\/fmed.2025.1631053","type":"journal-article","created":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T05:27:48Z","timestamp":1754630868000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":48,"title":["Diabetic kidney disease: from pathogenesis to multimodal therapy\u2013current evidence and future directions"],"prefix":"10.3389","volume":"12","author":[{"given":"Hui","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keding","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hairui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bowen","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manyi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jielian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","article-title":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","year":"2022","journal-title":"Kidney Int."},{"key":"B2","doi-asserted-by":"publisher","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res Clin Pract."},{"key":"B3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.4103\/1110-9165.197379","article-title":"Diabetic kidney disease: difference in the prevalence and risk factors worldwide","volume":"16","author":"Gheith","year":"2016","journal-title":"J Egypt Soc Nephrol Transplant."},{"key":"B4","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1681\/ASN.2012070718","article-title":"Kidney disease and increased mortality risk in type 2 diabetes","volume":"24","author":"Afkarian","year":"2013","journal-title":"J Am Soc Nephrol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41581-024-00827-z","article-title":"Combination therapy for kidney disease in people with diabetes mellitus","volume":"20","author":"van Raalte","year":"2024","journal-title":"Nat Rev Nephrol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1111\/dom.15559","article-title":"The potential for improved outcomes in the prevention and therapy of diabetic kidney disease through \u201cstacking\u201d of drugs from different classes","volume":"26","author":"Bell","year":"2024","journal-title":"Diabetes Obes Metab."},{"key":"B7","doi-asserted-by":"publisher","first-page":"7349","DOI":"10.3390\/jcm12237349","article-title":"Pathomechanisms of diabetic kidney disease","volume":"12","author":"Sinha","year":"2023","journal-title":"J Clin Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1681\/ASN.2006121362","article-title":"Mechanical forces in diabetic kidney disease: a trigger for impaired glucose metabolism","volume":"18","author":"Gnudi","year":"2007","journal-title":"J Am Soc Nephrol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1080\/13813455.2020.1797106","article-title":"Role of advanced glycation end products and insulin resistance in diabetic nephropathy","volume":"129","author":"Parwani","year":"2023","journal-title":"Arch Physiol Biochem."},{"key":"B10","doi-asserted-by":"publisher","first-page":"37264","DOI":"10.1021\/acsomega.3c05085","article-title":"Crosstalk between aldosterone and glycation through rac-1 induces diabetic nephropathy","volume":"8","author":"Apte","year":"2023","journal-title":"ACS Omega."},{"key":"B11","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12944-017-0522-6","article-title":"Advanced glycation end products (AGEs) increase renal lipid accumulation: a pathogenic factor of diabetic nephropathy (DN)","volume":"16","author":"Yuan","year":"2017","journal-title":"Lipids Health Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.2337\/diabetes.53.10.2653","article-title":"Glycation inactivation of the complement regulatory protein CD59: a possible role in the pathogenesis of the vascular complications of human diabetes","volume":"53","author":"Qin","year":"2004","journal-title":"Diabetes."},{"key":"B13","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1046\/j.1523-1755.2000.07703.x","article-title":"Role of the hexosamine biosynthetic pathway in diabetic nephropathy","volume":"77","author":"Schleicher","year":"2000","journal-title":"Kidney Int Suppl."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1186\/s41100-016-0028-0","article-title":"Signaling pathways in diabetic nephropathy","volume":"31","author":"Kawanami","year":"2016","journal-title":"Histol Histopathol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1172199","DOI":"10.3389\/fendo.2023.1172199","article-title":"Bone morphogenetic protein-7 attenuates pancreatic damage under diabetic conditions and prevents progression to diabetic nephropathy via inhibition of ferroptosis","volume":"14","author":"Song","year":"2023","journal-title":"Front Endocrinol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"525","DOI":"10.3390\/biom9100525","article-title":"All-trans retinoic acid attenuates fibrotic processes by downregulating TGF-\u03b21\/Smad3 in early diabetic nephropathy","volume":"9","author":"Sierra-Mondragon","year":"2019","journal-title":"Biomolecules."},{"key":"B17","doi-asserted-by":"publisher","first-page":"F134","DOI":"10.1152\/ajprenal.00199.2003","article-title":"Suppressions of chronic glomerular injuries and TGF-beta 1 production by HGF in attenuation of murine diabetic nephropathy","volume":"286","author":"Mizuno","year":"2004","journal-title":"Am J Physiol Renal Physiol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1294317","DOI":"10.3389\/fimmu.2023.1294317","article-title":"Ferroptosis: an important player in the inflammatory response in diabetic nephropathy","volume":"14","author":"Li","year":"2023","journal-title":"Front Immunol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3389\/fphar.2019.00027","article-title":"Ferulic acid protects hyperglycemia-induced kidney damage by regulating oxidative insult, inflammation and autophagy","volume":"10","author":"Chowdhury","year":"2019","journal-title":"Front Pharmacol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"716","DOI":"10.2174\/1874467215666211217122523","article-title":"Therapeutic potential of resveratrol in diabetic nephropathy according to molecular signaling","volume":"15","author":"Salami","year":"2022","journal-title":"Curr Mol Pharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1139444","DOI":"10.3389\/fendo.2023.1139444","article-title":"Autophagy and its therapeutic potential in diabetic nephropathy","volume":"14","author":"Han","year":"2023","journal-title":"Front Endocrinol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e60546","DOI":"10.1371\/journal.pone.0060546","article-title":"Autophagy attenuates diabetic glomerular damage through protection of hyperglycemia-induced podocyte injury","volume":"8","author":"Fang","year":"2013","journal-title":"PLoS ONE."},{"key":"B23","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/nrneph.2012.19","article-title":"Glomerular hyperfiltration: definitions, mechanisms and clinical implications","volume":"8","author":"Helal","year":"2012","journal-title":"Nat Rev Nephrol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"dmm050438","DOI":"10.1242\/dmm.050438","article-title":"A zebrafish model of diabetic nephropathy shows hyperglycemia, proteinuria and activation of the PI3K\/akt pathway","volume":"17","author":"Zang","year":"2024","journal-title":"Dis Model Mech"},{"key":"B25","doi-asserted-by":"publisher","first-page":"505","DOI":"10.3390\/pharmaceutics16040505","article-title":"Phloretamide protects against diabetic kidney damage and dysfunction in diabetic rats by attenuating hyperglycemia and hyperlipidemia, suppressing NF-\u03ba\u03b2, and upregulating Nrf2","volume":"16","author":"Al-Hussan","year":"2024","journal-title":"Pharmaceutics."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5414\/CN110223","article-title":"Serum interleukin-6 levels predict kidney disease progression in diabetic nephropathy","volume":"97","author":"Sanchez-Alamo","year":"2022","journal-title":"Clin Nephrol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"6193407","DOI":"10.1155\/2020\/6193407","article-title":"The interplay of renin-angiotensin system and toll-like receptor 4 in the inflammation of diabetic nephropathy","volume":"2020","author":"Feng","year":"2020","journal-title":"J Immunol Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.3892\/ijmm.2019.4163","article-title":"Role of the thioredoxin interacting protein in diabetic nephropathy and the mechanism of regulating NOD-like receptor protein 3 inflammatory corpuscle","volume":"43","author":"Gu","year":"2019","journal-title":"Int J Mol Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"609223","DOI":"10.3389\/fphys.2020.609223","article-title":"Patterns of toll-like receptor expressions and inflammatory cytokine levels and their implications in the progress of insulin resistance and diabetic nephropathy in type 2 diabetic patients","volume":"11","author":"Aly","year":"2020","journal-title":"Front Physiol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"75","DOI":"10.26402\/jpp.2024.6.05","article-title":"Mechanisms of resveratrol in alleviating diabetic nephropathy: focus on tumor necrosis factor receptor-related factor expression and toll-like reeptor 4\/nuclear factor-kappaB signaling pathway","author":"Sun","year":"2024","journal-title":"J Physiol Pharmacol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s10719-021-10035-7","article-title":"The association between serum interleukin-1 beta and heparin sulphate in diabetic nephropathy patients","volume":"38","author":"Jiang","year":"2021","journal-title":"Glycoconj J."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1072288","DOI":"10.3389\/fendo.2023.1072288","article-title":"The association of cell adhesion molecules and selectins (VCAM-1, ICAM-1, E-selectin, L-selectin, and P-selectin) with microvascular complications in patients with type 2 diabetes: a follow-up study","volume":"14","author":"Siddiqui","year":"2023","journal-title":"Front Endocrinol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"393","DOI":"10.4239\/wjd.v5.i3.393","article-title":"Diabetic nephropathy and inflammation","volume":"5","author":"Duran-Salgado","year":"2014","journal-title":"World J Diabetes."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.2337\/db11-1546","article-title":"Alagebrium reduces glomerular fibrogenesis and inflammation beyond preventing RAGE activation in diabetic apolipoprotein E knockout mice","volume":"61","author":"Watson","year":"2012","journal-title":"Diabetes."},{"key":"B35","doi-asserted-by":"publisher","first-page":"101","DOI":"10.4161\/oxim.3.2.11148","article-title":"Advanced glycation end products, oxidative stress and diabetic nephropathy","volume":"3","author":"Yamagishi","year":"2010","journal-title":"Oxid Med Cell Longev."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.2147\/DMSO.S450695","article-title":"Autophagy, pyroptosis and ferroptosis are rising stars in the pathogenesis of diabetic nephropathy","volume":"17","author":"Li","year":"2024","journal-title":"Diabetes Metab Syndr Obes Targets Ther."},{"key":"B37","doi-asserted-by":"publisher","first-page":"e15825","DOI":"10.14814\/phy2.15825","article-title":"Transcriptomic analysis reveals partial epithelial-mesenchymal transition and inflammation as common pathogenic mechanisms in hypertensive nephrosclerosis and type 2 diabetic nephropathy","volume":"11","author":"Nordb\u00f8","year":"2023","journal-title":"Physiol Rep."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1429420","DOI":"10.3389\/fendo.2024.1429420","article-title":"Mitochondrial dysfunction in diabetic nephropathy: insights and therapeutic avenues from traditional Chinese medicine","volume":"15","author":"Zhao","year":"2024","journal-title":"Front Endocrinol."},{"key":"B39","first-page":"1009","article-title":"Treatment of berberine alleviates diabetic nephropathy by reducing iron overload and inhibiting oxidative stress","volume":"38","author":"Wang","year":"2023","journal-title":"Histol Histopathol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"404","DOI":"10.3390\/antiox10030404","article-title":"Oxidized albumin as a mediator of kidney disease","volume":"10","author":"Figueroa","year":"2021","journal-title":"Antioxid Basel Switz."},{"key":"B41","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ejim.2019.07.035","article-title":"Serum 8-hydroxydeoxyguanosine, a marker of oxidative DNA damage, is associated with mortality independent of inflammation in chronic kidney disease","volume":"68","author":"Dai","year":"2019","journal-title":"Eur J Intern Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13098-024-01280-5","article-title":"SGLT2i relieve proteinuria in diabetic nephropathy patients potentially by inhibiting renal oxidative stress rather than through AGEs pathway","volume":"16","author":"Zeng","year":"2024","journal-title":"Diabetol Metab Syndr."},{"key":"B43","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.bbamcr.2018.02.010","article-title":"Nrf2-Keap1 signaling in oxidative and reductive stress","volume":"1865","author":"Bellezza","year":"2018","journal-title":"Biochim Biophys Acta Mol Cell Res."},{"key":"B44","doi-asserted-by":"publisher","first-page":"e38864","DOI":"10.1097\/MD.0000000000038864","article-title":"Circulating inflammatory factors and risk causality associated with type 2 diabetic nephropathy: a Mendelian randomization and bioinformatics study","volume":"103","author":"Hu","year":"2024","journal-title":"Medicine."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.2174\/1389450123666220820110801","article-title":"Diabetic nephropathy: pathogenesis to cure","volume":"23","author":"Kushwaha","year":"2022","journal-title":"Curr Drug Targets."},{"key":"B46","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/s41419-022-04628-9","article-title":"Targeting ferroptosis in acute kidney injury","volume":"13","author":"Ni","year":"2022","journal-title":"Cell Death Dis."},{"key":"B47","doi-asserted-by":"publisher","first-page":"872918","DOI":"10.3389\/fendo.2022.872918","article-title":"Update on pathogenesis of glomerular hyperfiltration in early diabetic kidney disease","volume":"13","author":"Yang","year":"2022","journal-title":"Front Endocrinol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"554","DOI":"10.2337\/db24-0553","article-title":"Renal tubule-specific angiotensinogen deletion attenuates SGLT2 expression and ameliorates diabetic kidney disease in murine models of type 1 diabetes","volume":"74","author":"Yang","year":"2025","journal-title":"Diabetes."},{"key":"B49","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.2337\/db21-0154","article-title":"Intraglomerular dysfunction predicts kidney failure in type 2 diabetes","volume":"70","author":"Saulnier","year":"2021","journal-title":"Diabetes."},{"key":"B50","doi-asserted-by":"publisher","first-page":"16518","DOI":"10.3390\/ijms242216518","article-title":"Effects of mechanical stress on endothelial cells in situ and in vitro","volume":"24","author":"Katoh","year":"2023","journal-title":"Int J Mol Sci."},{"key":"B51","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.vph.2017.09.002","article-title":"Regulation and function of endothelial glycocalyx layer in vascular diseases","volume":"100","author":"Sieve","year":"2018","journal-title":"Vascul Pharmacol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.2174\/0929867324666170705124647","article-title":"Glomerular endothelium and its impact on glomerular filtration barrier in diabetes: are the gaps still illusive?","volume":"25","author":"Ndisang","year":"2018","journal-title":"Curr Med Chem."},{"key":"B53","doi-asserted-by":"publisher","first-page":"964","DOI":"10.2337\/db23-0455","article-title":"Adiponectin reduces glomerular endothelial glycocalyx disruption and restores glomerular barrier function in a mouse model of type 2 diabetes","volume":"73","author":"Fawaz","year":"2024","journal-title":"Diabetes."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1042\/CS20220208","article-title":"Dysregulated haemostasis in thrombo-inflammatory disease","volume":"136","author":"Klavina","year":"2022","journal-title":"Clin Sci."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1113\/jphysiol.2011.205013","article-title":"Combined inhibition of nitric oxide and vasodilating prostaglandins abolishes forearm vasodilatation to systemic hypoxia in healthy humans","volume":"589","author":"Markwald","year":"2011","journal-title":"J Physiol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3390\/ijms26010113","article-title":"Direct vascular effects of angiotensin II (a systematic short review)","volume":"26","author":"N\u00e1dasy","year":"2024","journal-title":"Int J Mol Sci."},{"key":"B57","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/hr.2015.55","article-title":"TLR4 is a critical regulator of angiotensin II-induced vascular remodeling: the roles of extracellular SOD and NADPH oxidase","volume":"38","author":"Nakashima","year":"2015","journal-title":"Hypertens Res."},{"key":"B58","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1111\/bph.14687","article-title":"Blockade of myeloid differentiation 2 attenuates diabetic nephropathy by reducing activation of the renin-angiotensin system in mouse kidneys","volume":"176","author":"Wang","year":"2019","journal-title":"Br J Pharmacol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1038\/s41401-019-0326-5","article-title":"Gut microbiota dysbiosis-induced activation of the intrarenal renin-angiotensin system is involved in kidney injuries in rat diabetic nephropathy","volume":"41","author":"Lu","year":"2020","journal-title":"Acta Pharmacol Sin."},{"key":"B60","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1530\/eje.0.1460687","article-title":"Nitric oxide modulation of renal and cardiac hemodynamics in type 2 diabetes","volume":"146","author":"Dalla Vestra","year":"2002","journal-title":"Eur J Endocrinol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"F761","DOI":"10.1152\/ajprenal.00552.2020","article-title":"Effects of SGLT2 inhibitor and dietary NaCl on glomerular hemodynamics assessed by micropuncture in diabetic rats","volume":"320","author":"Thomson","year":"2021","journal-title":"Am J Physiol Renal Physiol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1038\/sj.jhh.1002221","article-title":"Renin inhibition: the holy grail of renin-angiotensin system blockade?","volume":"21","author":"McInnes","year":"2007","journal-title":"J Hum Hypertens."},{"key":"B63","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ijchv.2014.03.005","article-title":"Mineralocorticoid receptor antagonist in heart failure: past, present and future perspectives","volume":"3","author":"Vizzardi","year":"2014","journal-title":"Int J Cardiol Heart Vessels."},{"key":"B64","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3390\/genes15010078","article-title":"Liquid biopsy: a new avenue for the diagnosis of kidney disease: diabetic kidney disease, renal cancer, and IgA nephropathy","volume":"15","author":"Dybiec","year":"2024","journal-title":"Genes."},{"key":"B65","doi-asserted-by":"publisher","first-page":"759299","DOI":"10.3389\/fphar.2021.759299","article-title":"Epigenetic alterations in podocytes in diabetic nephropathy","volume":"12","author":"Sugita","year":"2021","journal-title":"Front Pharmacol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1042\/EBC20190037","article-title":"The DNA methylation landscape in cancer","volume":"63","author":"Skvortsova","year":"2019","journal-title":"Essays Biochem."},{"key":"B67","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1089\/ars.2017.7278","article-title":"Long noncoding RNA LINC01619 regulates MicroRNA-27a\/forkhead box protein O1 and endoplasmic reticulum stress-mediated podocyte injury in diabetic nephropathy","volume":"29","author":"Bai","year":"2018","journal-title":"Antioxid Redox Signal."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1515\/med-2021-0328","article-title":"Long noncoding RNA MIAT inhibits the progression of diabetic nephropathy and the activation of NF-\u03baB pathway in high glucose-treated renal tubular epithelial cells by the miR-182-5p\/GPRC5A axis","volume":"16","author":"Dong","year":"2021","journal-title":"Open Med Wars Pol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"7108","DOI":"10.3390\/ijms23137108","article-title":"Are alterations in DNA methylation related to CKD development?","volume":"23","author":"Rysz","year":"2022","journal-title":"Int J Mol Sci."},{"key":"B70","doi-asserted-by":"publisher","first-page":"6633","DOI":"10.1002\/jcp.27412","article-title":"Long noncoding RNA Gm6135 functions as a competitive endogenous RNA to regulate toll-like receptor 4 expression by sponging miR-203-3p in diabetic nephropathy","volume":"234","author":"Ji","year":"2019","journal-title":"J Cell Physiol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1159\/000495590","article-title":"The long noncoding RNA 150Rik promotes mesangial cell proliferation via miR-451\/IGF1R\/p38 MAPK signaling in diabetic nephropathy","volume":"51","author":"Zhang","year":"2018","journal-title":"Cell Physiol Biochem."},{"key":"B72","doi-asserted-by":"publisher","first-page":"3785","DOI":"10.3892\/mmr.2020.11486","article-title":"A novel identified circular RNA, circ_0000491, aggravates the extracellular matrix of diabetic nephropathy glomerular mesangial cells through suppressing miR-101b by targeting TGF\u03b2RI","volume":"22","author":"Mou","year":"2020","journal-title":"Mol Med Rep."},{"key":"B73","doi-asserted-by":"publisher","first-page":"654148","DOI":"10.1155\/2014\/654148","article-title":"Histone lysine methylation in diabetic nephropathy","volume":"2014","author":"Sun","year":"2014","journal-title":"J Diabetes Res."},{"key":"B74","doi-asserted-by":"publisher","first-page":"e70046","DOI":"10.1111\/jne.70046","article-title":"Maternal high fat and high sugar diet impacts on key DNA methylation enzymes in offspring brain in a sex-specific manner","author":"Hor","year":"2025","journal-title":"J Neuroendocrinol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1113\/jphysiol.2013.266411","article-title":"Apelin inhibits the development of diabetic nephropathy by regulating histone acetylation in Akita mouse","volume":"592","author":"Chen","year":"2014","journal-title":"J Physiol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.bbadis.2014.11.006","article-title":"Novel curcumin analog C66 prevents diabetic nephropathy via JNK pathway with the involvement of p300\/CBP-mediated histone acetylation","volume":"1852","author":"Wang","year":"2015","journal-title":"Biochim Biophys Acta."},{"key":"B77","doi-asserted-by":"publisher","first-page":"11555","DOI":"10.1096\/fj.201900703R","article-title":"BRD4 inhibition regulates MAPK, NF-\u03baB signals, and autophagy to suppress MMP-13 expression in diabetic intervertebral disc degeneration","volume":"33","author":"Wang","year":"2019","journal-title":"FASEB."},{"key":"B78","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/epigenomes8010010","article-title":"Exploring transcriptional regulation of beta cell SASP by BRD4-associated proteins and cell cycle control protein p21","volume":"8","author":"Manji","year":"2024","journal-title":"Epigenomes."},{"key":"B79","doi-asserted-by":"publisher","first-page":"102605","DOI":"10.1016\/j.jbc.2022.102605","article-title":"Long noncoding RNA SNHG5 promotes podocyte injury via the microRNA-26a-5p\/TRPC6 pathway in diabetic nephropathy","volume":"298","author":"Zhou","year":"2022","journal-title":"J Biol Chem."},{"key":"B80","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.2337\/db13-1810","article-title":"Role of transcription factor acetylation in diabetic kidney disease","volume":"63","author":"Liu","year":"2014","journal-title":"Diabetes."},{"key":"B81","doi-asserted-by":"publisher","first-page":"110655","DOI":"10.1016\/j.biopha.2020.110655","article-title":"AGE\/RAGE signaling-mediated endoplasmic reticulum stress and future prospects in non-coding RNA therapeutics for diabetic nephropathy","volume":"131","author":"Pathomthongtaweechai","year":"2020","journal-title":"Biomed Pharmacother."},{"key":"B82","doi-asserted-by":"publisher","first-page":"e18561","DOI":"10.1111\/jcmm.18561","article-title":"Long non-coding RNA-mediated modulation of endoplasmic reticulum stress under pathological conditions","volume":"28","author":"\u00c7ift\u00e7i","year":"2024","journal-title":"J Cell Mol Med."},{"key":"B83","doi-asserted-by":"publisher","first-page":"126911","DOI":"10.1016\/j.jtemb.2021.126911","article-title":"The role of non-coding RNAs in ferroptosis regulation","volume":"70","author":"Qi","year":"2022","journal-title":"J Trace Elem Med Biol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s00424-020-02352-x","article-title":"Gut microbiota and chronic kidney disease: evidences and mechanisms that mediate a new communication in the gastrointestinal-renal axis","volume":"472","author":"Rukavina Mikusic","year":"2020","journal-title":"Pflugers Arch."},{"key":"B85","doi-asserted-by":"publisher","first-page":"e00017","DOI":"10.1097\/IMNA-D-23-00017","article-title":"Bibliometric analysis of the relationship between gut microbiota and chronic kidney disease from 2001\u20132022","volume":"11","author":"Tao","year":"2024","journal-title":"Integr Med Nephrol Androl."},{"key":"B86","doi-asserted-by":"publisher","first-page":"2517402","DOI":"10.1080\/0886022X.2025.2517402","article-title":"Gut microbiota implication in diabetic kidney disease: mechanisms and novel therapeutic strategies","volume":"47","author":"Zhang","year":"2025","journal-title":"Ren Fail."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1441415","DOI":"10.3389\/fendo.2024.1441415","article-title":"Intestinal flora and bile acid interactions impact the progression of diabetic kidney disease","volume":"15","author":"Xu","year":"2024","journal-title":"Front Endocrinol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1080\/0886022X.2018.1561376","article-title":"Review of the efficacy of AST-120 (KREMEZIN\u00ae) on renal function in chronic kidney disease patients","volume":"41","author":"Asai","year":"2019","journal-title":"Ren Fail."},{"key":"B89","doi-asserted-by":"publisher","first-page":"252","DOI":"10.3390\/toxins13040252","article-title":"The impact of CKD on uremic toxins and gut microbiota","volume":"13","author":"Rysz","year":"2021","journal-title":"Toxins."},{"key":"B90","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3390\/toxins14040280","article-title":"Uremic toxins and cardiovascular risk in chronic kidney disease: what have we learned recently beyond the past findings?","volume":"14","author":"El Chamieh","year":"2022","journal-title":"Toxins."},{"key":"B91","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.3390\/nu17071247","article-title":"Impact of gut microbiome modulation on uremic toxin reduction in chronic kidney disease: a systematic review and network meta-analysis","volume":"17","author":"Cedillo-Flores","year":"2025","journal-title":"Nutrients."},{"key":"B92","doi-asserted-by":"publisher","first-page":"1359432","DOI":"10.3389\/fcimb.2024.1359432","article-title":"Gut microbiota microbial metabolites in diabetic nephropathy patients: far to go","volume":"14","author":"Yu","year":"2024","journal-title":"Front Cell Infect Microbiol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/nep.13874","article-title":"Gut microbiota, key to unlocking the door of diabetic kidney disease","volume":"26","author":"Wang","year":"2021","journal-title":"Nephrol Carlton Vic."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1231621","DOI":"10.3389\/fphys.2023.1231621","article-title":"The pathogenic role of intestinal flora metabolites in diabetic nephropathy","volume":"14","author":"Tian","year":"2023","journal-title":"Front Physiol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.3892\/etm.2019.7943","article-title":"Dysbiosis of gram-negative gut microbiota and the associated serum lipopolysaccharide exacerbates inflammation in type 2 diabetic patients with chronic kidney disease","volume":"18","author":"Salguero","year":"2019","journal-title":"Exp Ther Med."},{"key":"B96","doi-asserted-by":"publisher","first-page":"648","DOI":"10.3390\/toxins14100648","article-title":"Homeostasis in the gut microbiota in chronic kidney disease","volume":"14","author":"Bhargava","year":"2022","journal-title":"Toxins."},{"key":"B97","doi-asserted-by":"publisher","first-page":"1490314","DOI":"10.3389\/fmed.2024.1490314","article-title":"Research progress of gut microbiome and diabetic nephropathy","volume":"11","author":"Chu","year":"2024","journal-title":"Front Med."},{"key":"B98","doi-asserted-by":"publisher","first-page":"1018093","DOI":"10.3389\/fendo.2022.1018093","article-title":"systematic review and meta-analysis of gut microbiota in diabetic kidney disease: comparisons with diabetes mellitus, non-diabetic kidney disease, and healthy individuals","volume":"13","author":"Han","year":"2022","journal-title":"Front Endocrinol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"7379","DOI":"10.3390\/ijms25137379","article-title":"The role of short chain fatty acids in inflammation and body health","volume":"25","author":"Du","year":"2024","journal-title":"Int J Mol Sci."},{"key":"B100","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.3390\/biom14091153","article-title":"Diabetic kidney disease: contribution of phenyl sulfate derived from dietary tyrosine upon gut microbiota catabolism","volume":"14","author":"Liu","year":"2024","journal-title":"Biomolecules."},{"key":"B101","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/bph.16219","article-title":"Lactobacillus species ameliorate membranous nephropathy through inhibiting the aryl hydrocarbon receptor pathway via tryptophan-produced indole metabolites","volume":"181","author":"Miao","year":"2024","journal-title":"Br J Pharmacol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"682482","DOI":"10.3389\/fphys.2021.682482","article-title":"Trimethylamine N-oxide exacerbates renal inflammation and fibrosis in rats with diabetic kidney disease","volume":"12","author":"Fang","year":"2021","journal-title":"Front Physiol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"964389","DOI":"10.3389\/fendo.2022.964389","article-title":"The harmful intestinal microbial community accumulates during DKD exacerbation and microbiome-metabolome combined validation in a mouse model","volume":"13","author":"Shang","year":"2022","journal-title":"Front Endocrinol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41392-024-01913-1","article-title":"Targeting Lactobacillus johnsonii to reverse chronic kidney disease","volume":"9","author":"Miao","year":"2024","journal-title":"Signal Transduct Target Ther."},{"key":"B105","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1681\/ASN.2014101047","article-title":"Uremic toxicity of advanced glycation end products in CKD","volume":"27","author":"Stinghen","year":"2016","journal-title":"J Am Soc Nephrol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"e14798","DOI":"10.1111\/nmo.14798","article-title":"Small intestinal bacterial overgrowth in diabetic gastroenteropathy","volume":"36","author":"Varma","year":"2024","journal-title":"Neurogastroenterol Motil."},{"key":"B107","doi-asserted-by":"publisher","first-page":"e220542","DOI":"10.1530\/EC-22-0542","article-title":"Elevated serum trimethylamine oxide levels as potential biomarker for diabetic kidney disease","volume":"12","author":"Huang","year":"2023","journal-title":"Endocr Connect."},{"key":"B108","doi-asserted-by":"publisher","first-page":"15481","DOI":"10.1038\/s41598-025-00237-6","article-title":"Characterization of gut dysbiosis and intestinal barrier dysfunction in patients with metabolic dysfunction-associated steatotic liver disease and chronic kidney disease: a comparative study","volume":"15","author":"Dissayabutra","year":"2025","journal-title":"Sci Rep."},{"key":"B109","doi-asserted-by":"publisher","first-page":"F664","DOI":"10.1152\/ajprenal.00292.2020","article-title":"Decreased secretion and profibrotic activity of tubular exosomes in diabetic kidney disease","volume":"319","author":"Wen","year":"2020","journal-title":"Am J Physiol Renal Physiol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"9371","DOI":"10.1038\/s41598-017-09907-6","article-title":"Exosomes from high glucose-treated glomerular endothelial cells trigger the epithelial-mesenchymal transition and dysfunction of podocytes","volume":"7","author":"Wu","year":"2017","journal-title":"Sci Rep."},{"key":"B111","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1159\/000529709","article-title":"Exosomes in diabetic kidney disease","volume":"9","author":"Wen","year":"2023","journal-title":"Kidney Dis Basel Switz."},{"key":"B112","doi-asserted-by":"publisher","first-page":"1525314","DOI":"10.3389\/fphar.2025.1525314","article-title":"Emerging roles of exosomes in the diagnosis and treatment of kidney diseases","volume":"16","author":"Cao","year":"2025","journal-title":"Front Pharmacol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"9279","DOI":"10.1096\/fj.201802427RRR","article-title":"Exosomes from high glucose-treated macrophages activate glomerular mesangial cells via TGF-\u03b21\/Smad3 pathway in vivo and in vitro","volume":"33","author":"Zhu","year":"2019","journal-title":"FASEB J."},{"key":"B114","doi-asserted-by":"publisher","first-page":"1740770","DOI":"10.1155\/2022\/1740770","article-title":"Mesangial cell-derived exosomal miR-4455 induces podocyte injury in IgA nephropathy by targeting ULK2","volume":"2022","author":"Yu","year":"2022","journal-title":"Oxid Med Cell Longev."},{"key":"B115","doi-asserted-by":"publisher","first-page":"4021","DOI":"10.7150\/ijbs.62478","article-title":"Tubular cell-derived exosomal miR-150-5p contributes to renal fibrosis following unilateral ischemia-reperfusion injury by activating fibroblast in vitro and in vivo","volume":"17","author":"Zhou","year":"2021","journal-title":"Int J Biol Sci."},{"key":"B116","doi-asserted-by":"publisher","first-page":"941143","DOI":"10.3389\/fphys.2022.941143","article-title":"What do we actually know about exosomal microRNAs in kidney diseases?","volume":"13","author":"Li","year":"2022","journal-title":"Front Physiol."},{"key":"B117","doi-asserted-by":"publisher","first-page":"e1147","DOI":"10.1002\/mgg3.1147","article-title":"Biochemical, serological, and genetic aspects related to gene HLA-DQB1 and its association with type 1 diabetes mellitus (T1DM)","volume":"8","author":"Singh","year":"2020","journal-title":"Mol Genet Genomic Med."},{"key":"B118","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3390\/biom10010100","article-title":"Autophagy function and regulation in kidney disease","volume":"10","author":"Kaushal","year":"2020","journal-title":"Biomolecules."},{"key":"B119","doi-asserted-by":"publisher","first-page":"tkac059","DOI":"10.1093\/burnst\/tkac059","article-title":"Autophagy in acute kidney injury and maladaptive kidney repair","volume":"11","author":"Xiang","year":"2023","journal-title":"Burns Trauma"},{"key":"B120","doi-asserted-by":"publisher","first-page":"963920","DOI":"10.3389\/fphar.2022.963920","article-title":"Autophagy in renal fibrosis: protection or promotion?","volume":"13","author":"Dai","year":"2022","journal-title":"Front Pharmacol."},{"key":"B121","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1042\/CS20210625","article-title":"Mechanisms of podocyte injury and implications for diabetic nephropathy","volume":"136","author":"Barutta","year":"2022","journal-title":"Clin Sci."},{"key":"B122","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.7150\/ijbs.81892","article-title":"Emerging role of ferroptosis in diabetic kidney disease: molecular mechanisms and therapeutic opportunities","volume":"19","author":"Wang","year":"2023","journal-title":"Int J Biol Sci."},{"key":"B123","doi-asserted-by":"publisher","first-page":"100243","DOI":"10.1016\/j.metop.2023.100243","article-title":"Ferroptosis in diabetic nephropathy: mechanisms and therapeutic implications","volume":"18","author":"Mengstie","year":"2023","journal-title":"Metab Open."},{"key":"B124","doi-asserted-by":"publisher","first-page":"e70067","DOI":"10.1002\/cbf.70067","article-title":"Iron metabolism and ferroptosis in diabetic kidney disease","volume":"43","author":"Mu","year":"2025","journal-title":"Cell Biochem Funct."},{"key":"B125","doi-asserted-by":"publisher","first-page":"1215292","DOI":"10.3389\/fendo.2023.1215292","article-title":"Ferroptosis: new insight into the mechanisms of diabetic nephropathy and retinopathy","volume":"14","author":"Li","year":"2023","journal-title":"Front Endocrinol."},{"key":"B126","doi-asserted-by":"publisher","first-page":"945976","DOI":"10.3389\/fendo.2022.945976","article-title":"Research progress on ferroptosis in diabetic kidney disease","volume":"13","author":"Wu","year":"2022","journal-title":"Front Endocrinol."},{"key":"B127","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41419-021-03452-x","article-title":"Characterization of ferroptosis in kidney tubular cell death under diabetic conditions","volume":"12","author":"Kim","year":"2021","journal-title":"Cell Death Dis."},{"key":"B128","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41581-019-0135-6","article-title":"Epigenetics and epigenomics in diabetic kidney disease and metabolic memory","volume":"15","author":"Kato","year":"2019","journal-title":"Nat Rev Nephrol."},{"key":"B129","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41392-023-01333-7","article-title":"Epigenetic regulation in metabolic diseases: mechanisms and advances in clinical study","volume":"8","author":"Wu","year":"2023","journal-title":"Signal Transduct Target Ther."},{"key":"B130","doi-asserted-by":"publisher","first-page":"931493","DOI":"10.3389\/fcell.2022.931493","article-title":"Epigenetic regulation of inflammatory signaling and inflammation-induced cancer","volume":"10","author":"Tan","year":"2022","journal-title":"Front Cell Dev Biol."},{"key":"B131","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s00535-013-0892-0","article-title":"Epigenetic histone methylation regulates transforming growth factor \u03b2-1 expression following bile duct ligation in rats","volume":"49","author":"Sheen-Chen","year":"2014","journal-title":"J Gastroenterol."},{"key":"B132","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.mam.2016.10.001","article-title":"Epigenetics in fibrosis","volume":"54","author":"O'Reilly","year":"2017","journal-title":"Mol Aspects Med."},{"key":"B133","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1042\/CS20160261","article-title":"Long non-coding RNAs-towards precision medicine in diabetic kidney disease?","volume":"130","author":"Panchapakesan","year":"2016","journal-title":"Clin Sci"},{"key":"B134","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1038\/s41467-025-57920-5","article-title":"Programmable mRNA therapeutics for controlled epigenomic modulation of single and multiplexed gene expression in diverse diseases","volume":"16","author":"O'Donnell","year":"2025","journal-title":"Nat Commun."},{"key":"B135","doi-asserted-by":"publisher","first-page":"6","DOI":"10.14341\/probl20095556-9","article-title":"Clinical significance of the ADVANCE study for a practitioner: possibility to treat and prevent complications of type 2 diabetes mellitus","volume":"55","author":"Shishkova","year":"2009","journal-title":"Probl Endokrinol."},{"key":"B136","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.2337\/dc19-1817","article-title":"Effects of intensive glycemic control on clinical outcomes among patients with type 2 diabetes with different levels of cardiovascular risk and hemoglobin A1c in the ADVANCE Trial","volume":"43","author":"Tian","year":"2020","journal-title":"Diabetes Care."},{"key":"B137","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1161\/CIRCULATIONAHA.108.191305","article-title":"Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the american diabetes association and a scientific statement of the American college of cardiology foundation and the American heart association","volume":"53","author":"Skyler","year":"2009","journal-title":"J Am Coll Cardiol."},{"key":"B138","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1001\/archinternmed.2011.2230","article-title":"Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes","volume":"172","author":"Coca","year":"2012","journal-title":"Arch Intern Med."},{"key":"B139","doi-asserted-by":"publisher","first-page":"184","DOI":"10.3390\/nu15010184","article-title":"Metabolic homeostasis of amino acids and diabetic kidney disease","volume":"15","author":"Liu","year":"2022","journal-title":"Nutrients."},{"key":"B140","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/jdi.12147","article-title":"Glycated hemoglobin variability and retinopathy progression in type 1 diabetes: is month-to-moth instability a better predictor?","volume":"5","author":"Chang","year":"2014","journal-title":"J Diabetes Investig."},{"key":"B141","doi-asserted-by":"publisher","first-page":"39","DOI":"10.5049\/EBP.2022.20.2.39","article-title":"Blood pressure control in patients with diabetic kidney disease","volume":"20","author":"Kim","year":"2022","journal-title":"Electrolyte Blood Press."},{"key":"B142","doi-asserted-by":"publisher","first-page":"e34572","DOI":"10.7759\/cureus.34572","article-title":"Lifestyle modifications and nutritional and therapeutic interventions in delaying the progression of chronic kidney disease: a review","volume":"15","author":"Alkhatib","year":"2023","journal-title":"Cureus."},{"key":"B143","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial","volume":"288","author":"Wright","year":"2002","journal-title":"JAMA."},{"key":"B144","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"UK prospective diabetes study (UKPDS) group","volume":"352","year":"1998","journal-title":"Lancet."},{"key":"B145","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1093\/eurheartj\/ehac395","article-title":"Hypertension management in patients with cardiovascular comorbidities","volume":"44","author":"Lauder","year":"2023","journal-title":"Eur Heart J."},{"key":"B146","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12911-023-02137-z","article-title":"Personalized hypertension treatment recommendations by a data-driven model","volume":"23","author":"Hu","year":"2023","journal-title":"BMC Med Inform Decis Mak."},{"key":"B147","doi-asserted-by":"publisher","first-page":"e15450","DOI":"10.1111\/dme.15450","article-title":"Current management of chronic kidney disease in type-2 diabetes-a tiered approach: an overview of the joint association of British clinical diabetologists and UK kidney association (ABCD-UKKA) guidelines","volume":"42","author":"Dasgupta","year":"2025","journal-title":"Diabet Med."},{"key":"B148","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1053\/j.ajkd.2015.09.020","article-title":"Cost-effectiveness of simvastatin plus ezetimibe for cardiovascular prevention in CKD: results of the study of heart and renal protection (SHARP)","volume":"67","author":"Mihaylova","year":"2016","journal-title":"Am J Kidney Dis."},{"key":"B149","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1080\/0886022X.2021.1915799","article-title":"Efficacy of statins on renal function in patients with chronic kidney disease: a systematic review and meta-analysis","volume":"43","author":"Zhao","year":"2021","journal-title":"Ren Fail."},{"key":"B150","doi-asserted-by":"publisher","first-page":"e027516","DOI":"10.1161\/JAHA.122.027516","article-title":"Association of low-density lipoprotein cholesterol levels during statin treatment with cardiovascular and renal outcomes in patients with moderate chronic kidney disease","volume":"11","author":"Yen","year":"2022","journal-title":"J Am Heart Assoc."},{"key":"B151","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s11892-015-0632-3","article-title":"Impact of lifestyle modification on diabetic kidney disease","volume":"15","author":"Onyenwenyi","year":"2015","journal-title":"Curr Diab Rep."},{"key":"B152","doi-asserted-by":"publisher","first-page":"CD006763","DOI":"10.1002\/14651858.CD006763.pub3","article-title":"Altered dietary salt intake for preventing diabetic kidney disease and its progression","volume":"1","author":"Hodson","year":"2023","journal-title":"Cochrane Database Syst Rev."},{"key":"B153","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1042\/CS20120352","article-title":"Association of dietary sodium intake with atherogenesis in experimental diabetes and with cardiovascular disease in patients with type 1 diabetes","volume":"124","author":"Tikellis","year":"2013","journal-title":"Clin Sci."},{"key":"B154","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1507\/endocrj.EJ21-0447","article-title":"Impact of salt intake on urinary albumin excretion in patients with type 2 diabetic nephropathy: a retrospective cohort study based on a generalized additive model","volume":"69","author":"Kotake","year":"2022","journal-title":"Endocr J."},{"key":"B155","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1210\/clinem\/dgac057","article-title":"Body mass index and risk of diabetic nephropathy: a Mendelian randomization study","volume":"107","author":"Lu","year":"2022","journal-title":"J Clin Endocrinol Metab."},{"key":"B156","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1111\/dom.13813","article-title":"Impact of intentional weight loss on diabetic kidney disease","volume":"21","author":"Holland","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"B157","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1038\/s41598-024-53333-4","article-title":"The effect of periodic resistance training on obese patients with type 2 diabetic nephropathy","volume":"14","author":"Li","year":"2024","journal-title":"Sci Rep."},{"key":"B158","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12882-021-02618-1","article-title":"Clinical practice guideline exercise and lifestyle in chronic kidney disease","volume":"23","author":"Baker","year":"2022","journal-title":"BMC Nephrol."},{"key":"B159","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.2337\/dci23-0030","article-title":"Diabetic nephropathy: update on pillars of therapy slowing progression","volume":"46","author":"Naaman","year":"2023","journal-title":"Diabetes Care."},{"key":"B160","doi-asserted-by":"publisher","first-page":"3969","DOI":"10.3390\/ijms25073969","article-title":"Molecular targets of novel therapeutics for diabetic kidney disease: a new era of nephroprotection","volume":"25","author":"Mazzieri","year":"2024","journal-title":"Int J Mol Sci."},{"key":"B161","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.123.067584","article-title":"Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria","volume":"149","author":"Neuen","year":"2024","journal-title":"Circulation."},{"key":"B162","doi-asserted-by":"publisher","first-page":"381","DOI":"10.7326\/M22-2904","article-title":"Diabetes management in chronic kidney disease: synopsis of the KDIGO 2022 clinical practice guideline update","volume":"176","author":"Navaneethan","year":"2023","journal-title":"Ann Intern Med."},{"key":"B163","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1161\/CIRCULATIONAHA.122.059595","article-title":"GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes","volume":"146","author":"Marx","year":"2022","journal-title":"Circulation."},{"key":"B164","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.3390\/jcm10132943","article-title":"Management of kidney failure in patients with diabetes mellitus: what are the best options?","volume":"10","author":"Buades","year":"2021","journal-title":"J Clin Med."},{"key":"B165","doi-asserted-by":"publisher","first-page":"7041","DOI":"10.3390\/jcm11237041","article-title":"Heart failure and cardiorenal syndrome: a narrative review on pathophysiology, diagnostic and therapeutic regimens-from a cardiologist's view","volume":"11","author":"Mitsas","year":"2022","journal-title":"J Clin Med."},{"key":"B166","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1161\/CIRCULATIONAHA.121.053766","article-title":"Incorporating SGLT2i and GLP-1RA for cardiovascular and kidney disease risk reduction: call for action to the cardiology community","volume":"144","author":"Nelson","year":"2021","journal-title":"Circulation."},{"key":"B167","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.2337\/dci22-0027","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American diabetes association (ADA) and kidney disease: improving global outcomes (KDIGO)","volume":"45","author":"de Boer","year":"2022","journal-title":"Diabetes Care."},{"key":"B168","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The collaborative study group","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med."},{"key":"B169","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med."},{"key":"B170","doi-asserted-by":"publisher","first-page":"S191","DOI":"10.1053\/ajkd.2001.27442","article-title":"A clinical trial in type 2 diabetic nephropathy","volume":"38","author":"Lewis","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"B171","doi-asserted-by":"publisher","first-page":"S99","DOI":"10.1111\/j.1523-1755.2004.09223.x","article-title":"Impact of irbesartan, blood pressure control, and proteinuria on renal outcomes in the irbesartan diabetic nephropathy trial","author":"Hunsicker","year":"2004","journal-title":"Kidney Int Suppl"},{"key":"B172","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1093\/ndt\/gfr696","article-title":"Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate: post hoc analysis of the irbesartan diabetic nephropathy trial","volume":"27","author":"Evans","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"B173","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1161\/CIRCULATIONAHA.123.065251","article-title":"Cardiorenal biomarkers, canagliflozin, and outcomes in diabetic kidney disease: the CREDENCE trial","volume":"148","author":"Januzzi","year":"2023","journal-title":"Circulation."},{"key":"B174","doi-asserted-by":"publisher","first-page":"713","DOI":"10.26442\/00403660.2021.6.200891","article-title":"The dapagliflozin and prevention of adverse outcomes in chronic kidney disease: results of the DAPA-CKD study","volume":"93","author":"Batyushin","year":"2021","journal-title":"Ter Arkh."},{"key":"B175","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1093\/ndt\/gfae203","article-title":"Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial","volume":"40","author":"Mayne","year":"2025","journal-title":"Nephrol Dial Transplant."},{"key":"B176","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.tem.2021.02.002","article-title":"Finerenone: a non-steroidal mineralocorticoid receptor blocker for diabetic kidney disease","volume":"32","author":"Verma","year":"2021","journal-title":"Trends Endocrinol Metab."},{"key":"B177","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med."},{"key":"B178","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med."},{"key":"B179","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J."},{"key":"B180","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.2337\/dc20-1622","article-title":"Changes in albuminuria predict cardiovascular and renal outcomes in type 2 diabetes: a post hoc analysis of the LEADER trial","volume":"44","author":"Persson","year":"2021","journal-title":"Diabetes Care."},{"key":"B181","doi-asserted-by":"publisher","first-page":"309","DOI":"10.14740\/cr1424","article-title":"Chronic kidney disease stage G4 in a diabetic patient improved by multi-disciplinary treatments based upon literature search for therapeutic evidence","volume":"13","author":"Yanai","year":"2022","journal-title":"Cardiol Res."},{"key":"B182","doi-asserted-by":"publisher","first-page":"662775","DOI":"10.3389\/fmed.2021.662775","article-title":"Evaluation of consistency of treatment response across regions-the LEADER trial in relation to the ICH E17 guideline","volume":"8","author":"Nielsen","year":"2021","journal-title":"Front Med."},{"key":"B183","doi-asserted-by":"publisher","first-page":"5157","DOI":"10.1111\/dom.15860","article-title":"Effect of semaglutide on primary prevention of diabetic kidney disease in people with type 2 diabetes: a post hoc analysis of the SUSTAIN 6 randomized controlled trial","volume":"26","author":"Wang","year":"2024","journal-title":"Diabetes Obes Metab."},{"key":"B184","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1093\/ndt\/gfad009","article-title":"The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease","volume":"38","author":"Rossing","year":"2023","journal-title":"Nephrol Dial Transplant."},{"key":"B185","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1093\/eurheartj\/ehae613","article-title":"Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial","volume":"46","author":"Mahaffey","year":"2025","journal-title":"Eur Heart J."},{"key":"B186","doi-asserted-by":"publisher","first-page":"1423191","DOI":"10.1155\/2016\/1423191","article-title":"Renal protective effect of DPP-4 inhibitors in type 2 diabetes mellitus patients: a cohort study","volume":"2016","author":"Kim","year":"2016","journal-title":"J Diabetes Res."},{"key":"B187","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1177\/2042098614523031","article-title":"Safety of dipeptidyl peptidase 4 inhibitors: a perspective review","volume":"5","author":"Karagiannis","year":"2014","journal-title":"Ther Adv Drug Saf."},{"key":"B188","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.2337\/dc18-0078","article-title":"Effects of pentoxifylline on soluble klotho concentrations and renal tubular cell expression in diabetic kidney disease","volume":"41","author":"Navarro-Gonz\u00e1lez","year":"2018","journal-title":"Diabetes Care."},{"key":"B189","doi-asserted-by":"publisher","first-page":"50","DOI":"10.2165\/00003495-198734010-00003","article-title":"Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy","volume":"34","author":"Ward","year":"1987","journal-title":"Drugs"},{"key":"B190","doi-asserted-by":"publisher","first-page":"e053019","DOI":"10.1136\/bmjopen-2021-053019","article-title":"Pentoxifylline in diabetic kidney disease (VA PTXRx): protocol for a pragmatic randomised controlled trial","volume":"11","author":"Leehey","year":"2021","journal-title":"BMJ Open."},{"key":"B191","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3945\/an.115.008433","article-title":"Dietary advanced glycation end products and their role in health and disease","volume":"6","author":"Uribarri","year":"2015","journal-title":"Adv Nutr Bethesda Md."},{"key":"B192","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1038\/s41598-017-02268-0","article-title":"Consumption of diets with low advanced glycation end products improves cardiometabolic parameters: meta-analysis of randomised controlled trials","volume":"7","author":"Baye","year":"2017","journal-title":"Sci Rep."},{"key":"B193","doi-asserted-by":"publisher","first-page":"143","DOI":"10.4045\/tidsskr.22.0822","article-title":"Diabetes and chronic kidney disease","author":"Mariampillai","year":"2023","journal-title":"Tidsskr Den Nor Laegeforening."},{"key":"B194","doi-asserted-by":"publisher","first-page":"1017459","DOI":"10.3389\/fmed.2023.1017459","article-title":"The association between vitamin D deficiency and risk of renal event: results from the Korean cohort study for outcomes in patients with chronic kidney disease (KNOW-CKD)","volume":"10","author":"Lee","year":"2023","journal-title":"Front Med."},{"key":"B195","doi-asserted-by":"publisher","first-page":"420","DOI":"10.3390\/medicina60030420","article-title":"Vitamin D deficiency, chronic kidney disease and periodontitis","volume":"60","author":"Ganimusa","year":"2024","journal-title":"Med Kaunas Lith."},{"key":"B196","doi-asserted-by":"publisher","first-page":"4579","DOI":"10.1172\/JCI67804","article-title":"A nonclassical vitamin D receptor pathway suppresses renal fibrosis","volume":"123","author":"Ito","year":"2013","journal-title":"J Clin Invest."},{"key":"B197","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1016\/S0140-6736(10)61032-X","article-title":"Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial","volume":"376","author":"de Zeeuw","year":"2010","journal-title":"Lancet."},{"key":"B198","doi-asserted-by":"publisher","first-page":"575","DOI":"10.3390\/nu12020575","article-title":"Vitamin D and endothelial function","volume":"12","author":"Kim","year":"2020","journal-title":"Nutrients."},{"key":"B199","doi-asserted-by":"publisher","first-page":"19450","DOI":"10.1074\/jbc.M113.467670","article-title":"Vitamin D receptor inhibits nuclear factor \u03baB activation by interacting with I\u03baB kinase \u03b2 protein","volume":"288","author":"Chen","year":"2013","journal-title":"J Biol Chem."},{"key":"B200","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.semnephrol.2013.07.005","article-title":"Vitamin D receptor signaling in renal and cardiovascular protection","volume":"33","author":"Li","year":"2013","journal-title":"Semin Nephrol."},{"key":"B201","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1159\/000480315","article-title":"VDA activation reduces proteinuria and high-glucose-induced injury of kidneys and podocytes by regulating Wnt signaling pathway","volume":"43","author":"Guo","year":"2017","journal-title":"Cell Physiol Biochem."},{"key":"B202","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1681\/ASN.2016040407","article-title":"Effects of vitamin D receptor activation and dietary sodium restriction on residual albuminuria in CKD: the ViRTUE-CKD trial","volume":"28","author":"Keyzer","year":"2017","journal-title":"J Am Soc Nephrol."},{"key":"B203","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1053\/j.ajkd.2023.04.015","article-title":"Novel therapies in diabetic kidney disease and risk of hyperkalemia: a review of the evidence from clinical trials","volume":"82","author":"Albakr","year":"2023","journal-title":"Am J Kidney Dis."},{"key":"B204","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/CIRCULATIONAHA.107.181940","article-title":"ACC\/AHA 2007 guidelines for the management of patients with unstable angina\/non-ST-elevation myocardial infarction: a report of the American college of cardiology\/american heart association task force on practice guidelines (writing committee to revise the 2002 guidelines for the management of patients with unstable angina\/non-ST-elevation myocardial infarction) developed in collaboration with the American college of emergency physicians, the society for cardiovascular angiography and interventions, and the society of thoracic surgeons endorsed by the American association of cardiovascular and pulmonary rehabilitation and the society for academic emergency medicine","volume":"50","author":"Anderson","year":"2007","journal-title":"J Am Coll Cardiol."},{"key":"B205","doi-asserted-by":"publisher","first-page":"sfad272","DOI":"10.1093\/ckj\/sfad272","article-title":"SGLT2 inhibitors and finerenone in non-diabetic CKD: a step into the (near) future?","volume":"17","author":"Theodorakopoulou","year":"2023","journal-title":"Clin Kidney J"},{"key":"B206","doi-asserted-by":"publisher","first-page":"A10533","DOI":"10.1161\/circ.146.suppl_1.10533","article-title":"Abstract 10533: cardiorenal effects of Sglt2 inhibitors and finerenone in type 2 diabetes and chronic kidney disease. Single, dual or triple therapy? A network meta-analysis","volume":"146","author":"Diaz Acevedo","year":"2022","journal-title":"Circulation."},{"key":"B207","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1007\/s13300-024-01591-w","article-title":"Summary of research: cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease-the FIDELITY pooled analysis","volume":"15","author":"Humle","year":"2024","journal-title":"Diabetes Ther."},{"key":"B208","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.2337\/figshare.20289009.v1","article-title":"Finerenone in patients with chronic kidney disease and type 2 diabetes by sodium-glucose cotransporter 2 inhibitor treatment: the FIDELITY analysis","volume":"45","author":"Rossing","year":"2022","journal-title":"Diabetes Care."},{"key":"B209","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1681\/ASN.2021070942","article-title":"Hyperkalemia risk with finerenone: results from the FIDELIO-DKD trial","volume":"33","author":"Agarwal","year":"2022","journal-title":"J Am Soc Nephrol."},{"key":"B210","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.2215\/CJN.0000000000000205","article-title":"Influence of SGLT2i and RAASi and their combination on risk of hyperkalemia in DKD: a network meta-analysis","volume":"18","author":"Luo","year":"2023","journal-title":"Clin J Am Soc Nephrol."},{"key":"B211","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12933-023-01840-5","article-title":"An analysis of DPV and DIVE registry patients with chronic kidney disease according to the finerenone phase III clinical trial selection criteria","volume":"22","author":"Bramlage","year":"2023","journal-title":"Cardiovasc Diabetol."},{"key":"B212","doi-asserted-by":"publisher","first-page":"1342831","DOI":"10.3389\/fphar.2024.1342831","article-title":"Use of bailing capsules (Cordyceps sinensis) in the treatment of chronic kidney disease: a meta-analysis and network pharmacology","volume":"15","author":"Tao","year":"2024","journal-title":"Front Pharmacol."},{"key":"B213","doi-asserted-by":"publisher","first-page":"155991","DOI":"10.1016\/j.phymed.2024.155991","article-title":"Astragaloside IV attenuates fatty acid-induced renal tubular injury in diabetic kidney disease by inhibiting fatty acid transport protein-2","volume":"134","author":"Wang","year":"2024","journal-title":"Phytomedicine."},{"key":"B214","doi-asserted-by":"publisher","first-page":"1480626","DOI":"10.3389\/fphar.2024.1480626","article-title":"Impact of baicalin and components of Scutellaria baicalensis on renal fibrosis of diabetic kidney disease","volume":"15","author":"Li","year":"2024","journal-title":"Front Pharmacol"},{"key":"B215","doi-asserted-by":"publisher","first-page":"155813","DOI":"10.1016\/j.phymed.2024.155813","article-title":"Puerarin suppresses macrophage M1 polarization to alleviate renal inflammatory injury through antagonizing TLR4\/MyD88-mediated NF-\u03baB p65 and JNK\/FoxO1 activation","volume":"132","author":"Hu","year":"2024","journal-title":"Phytomedicine."},{"key":"B216","doi-asserted-by":"publisher","first-page":"118066","DOI":"10.1016\/j.jep.2024.118066","article-title":"Hypolipidemic effect and gut microbiota regulation of gypenoside aglycones in rats fed a high-fat diet","volume":"328","author":"Xie","year":"2024","journal-title":"J Ethnopharmacol."},{"key":"B217","doi-asserted-by":"publisher","first-page":"e17550","DOI":"10.1016\/j.heliyon.2023.e17550","article-title":"Exploring the pharmacological mechanisms of Tripterygium wilfordii against diabetic kidney disease using network pharmacology and molecular docking","volume":"9","author":"Lu","year":"2023","journal-title":"Heliyon."},{"key":"B218","first-page":"138","article-title":"Panax notoginseng preparations as adjuvant therapy for diabetic kidney disease : a systematic review and meta-analysis","volume-title":"Pharm Biol.","author":"Tang","year":"2020"},{"key":"B219","doi-asserted-by":"publisher","first-page":"112131","DOI":"10.1016\/j.intimp.2024.112131","article-title":"Osthole ameliorates early diabetic kidney damage by suppressing oxidative stress, inflammation and inhibiting TGF-\u03b21\/smads signaling pathway","volume":"133","author":"Li","year":"2024","journal-title":"Int Immunopharmacol."},{"key":"B220","doi-asserted-by":"publisher","first-page":"1424644","DOI":"10.3389\/fmed.2024.1424644","article-title":"Integrating serum pharmacochemistry and network pharmacology to explore potential compounds and mechanisms of Alpiniae oxyphyllae fructus in the treatment of cellular senescence in diabetic kidney disease","volume":"11","author":"Yan","year":"2024","journal-title":"Front Med"},{"key":"B221","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/IMNA-D-22-00026","article-title":"New insights into traditional Chinese medicine in treatment of diabetic nephropathy","author":"Chung","year":"2023","journal-title":"Integr Med Nephrol Androl"},{"key":"B222","doi-asserted-by":"publisher","first-page":"5489","DOI":"10.7150\/ijbs.72977","article-title":"Prevents Smad3-dependent diabetic nephropathy by restoring pancreatic \u03b2-cell development in db\/db mice","volume":"18","author":"Chung","year":"2022","journal-title":"Int J Biol Sci."},{"key":"B223","doi-asserted-by":"publisher","first-page":"8871677","DOI":"10.1155\/2023\/8871677","article-title":"Role of gut microbiota, immune imbalance, and allostatic load in the occurrence and development of diabetic kidney disease","volume":"2023","author":"Han","year":"2023","journal-title":"J Diabetes Res."},{"key":"B224","doi-asserted-by":"publisher","first-page":"111061","DOI":"10.1016\/j.biopha.2020.111061","article-title":"QiDiTangShen granules modulated the gut microbiome composition and improved bile acid profiles in a mouse model of diabetic nephropathy","volume":"133","author":"Wei","year":"2021","journal-title":"Biomed Pharmacother."},{"key":"B225","doi-asserted-by":"publisher","first-page":"116257","DOI":"10.1016\/j.jep.2023.116257","article-title":"Yi-Shen-Hua-Shi granule ameliorates diabetic kidney disease by the \u201cgut-kidney axis\u201d","volume":"307","author":"Han","year":"2023","journal-title":"J Ethnopharmacol"},{"key":"B226","doi-asserted-by":"publisher","first-page":"e14171","DOI":"10.1016\/j.heliyon.2023.e14171","article-title":"Yishen huashi granule modulated lipid metabolism in diabetic nephropathy via PI3K\/AKT\/mTOR signaling pathways","volume":"9","author":"Zhao","year":"2023","journal-title":"Heliyon."},{"key":"B227","doi-asserted-by":"publisher","first-page":"110954","DOI":"10.1016\/j.biopha.2020.110954","article-title":"Anemarrhena asphodeloides modulates gut microbiota and restores pancreatic function in diabetic rats","volume":"133","author":"Yan","year":"2021","journal-title":"Biomed Pharmacother."},{"key":"B228","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/2045-3701-2-22","article-title":"The protective effect of peroxiredoxin II on oxidative stress induced apoptosis in pancreatic \u03b2-cells","volume":"2","author":"Zhao","year":"2012","journal-title":"Cell Biosci."},{"key":"B229","doi-asserted-by":"publisher","first-page":"719950","DOI":"10.3389\/fmed.2021.719950","article-title":"Qing-Re-Xiao-Zheng formula modulates gut microbiota and inhibits inflammation in mice with diabetic kidney disease","volume":"8","author":"Gao","year":"2021","journal-title":"Front Med."},{"key":"B230","doi-asserted-by":"publisher","first-page":"110325","DOI":"10.1016\/j.biopha.2020.110325","article-title":"Tangshen formula modulates gut microbiota and reduces gut-derived toxins in diabetic nephropathy rats","volume":"129","author":"Zhao","year":"2020","journal-title":"Biomed Pharmacother."},{"key":"B231","doi-asserted-by":"publisher","first-page":"1346168","DOI":"10.3389\/fphar.2024.1346168","article-title":"Effects of Bifidobacterium bifidum tetragonum tablets and Jin Gui Ren Qi Pill on intestinal flora and metabolism in patients with diabetic kidney disease","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Pharmacol"},{"key":"B232","doi-asserted-by":"publisher","first-page":"1424968","DOI":"10.3389\/fphar.2024.1424968","article-title":"Effects of Abelmoschus manihot (L","volume":"15","author":"Yu","year":"2024","journal-title":"Front Pharmacol"},{"key":"B233","doi-asserted-by":"publisher","first-page":"1009571","DOI":"10.3389\/fphar.2022.1009571","article-title":"Traditional Chinese medicine for the treatment of diabetic kidney disease: a study-level pooled analysis of 44 randomized controlled trials","volume":"13","author":"Liu","year":"2022","journal-title":"Front Pharmacol."},{"key":"B234","doi-asserted-by":"publisher","first-page":"e27614","DOI":"10.2196\/27614","article-title":"Deciphering the efficacy and mechanisms of Chinese herbal medicine for diabetic kidney disease by integrating web-based biochemical databases and real-world clinical data: retrospective cohort study","volume":"9","author":"Wu","year":"2021","journal-title":"JMIR Med Inform."},{"key":"B235","doi-asserted-by":"publisher","first-page":"1438266","DOI":"10.3389\/fmed.2024.1438266","article-title":"Perspectives of clinical research on Shen-Shuai-Ning in the treatment of diabetic nephropathy","volume":"11","author":"Gao","year":"2024","journal-title":"Front Med"},{"key":"B236","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/nep.14130","article-title":"Endothelin receptor antagonists in kidney protection for diabetic kidney disease and beyond?","volume":"28","author":"Chung","year":"2023","journal-title":"Nephrol Carlton Vic."},{"key":"B237","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/S0140-6736(23)00569-X","article-title":"Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial","volume":"401","author":"Heerspink","year":"2023","journal-title":"Lancet."},{"key":"B238","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1080\/1744666X.2024.2319132","article-title":"Sparsentan: the first and only non-immunosuppressive therapy for the reduction of proteinuria in IgA nephropathy","volume":"20","author":"Trachtman","year":"2024","journal-title":"Expert Rev Clin Immunol."},{"key":"B239","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1124\/mol.110.064980","article-title":"Genome-wide expression profiling revealed peripheral effects of cannabinoid receptor 1 inverse agonists in improving insulin sensitivity and metabolic parameters","volume":"78","author":"Zhao","year":"2010","journal-title":"Mol Pharmacol."},{"key":"B240","doi-asserted-by":"publisher","first-page":"1138416","DOI":"10.3389\/fneph.2023.1138416","article-title":"Therapeutic potential of a novel peripherally restricted CB1R inverse agonist on the progression of diabetic nephropathy","volume":"3","author":"Jacquot","year":"2023","journal-title":"Front Nephrol."},{"key":"B241","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.3390\/biom12091227","article-title":"Oxidative stress and NRF2\/KEAP1\/ARE pathway in diabetic kidney disease (DKD): new perspectives","volume":"12","author":"Tanase","year":"2022","journal-title":"Biomolecules."},{"key":"B242","doi-asserted-by":"publisher","first-page":"102525","DOI":"10.1016\/j.redox.2022.102525","article-title":"Nrf2 deficiency deteriorates diabetic kidney disease in akita model mice","volume":"58","author":"Liu","year":"2022","journal-title":"Redox Biol."},{"key":"B243","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1038\/s41467-025-56891-x","article-title":"CerS6 links ceramide metabolism to innate immune responses in diabetic kidney disease","volume":"16","author":"Zhu","year":"2025","journal-title":"Nat Commun."},{"key":"B244","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.molmet.2018.12.008","article-title":"The role of C16:0 ceramide in the development of obesity and type 2 diabetes: CerS6 inhibition as a novel therapeutic approach","volume":"21","author":"Raichur","year":"2019","journal-title":"Mol Metab."},{"key":"B245","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1166\/mex.2021.1888","article-title":"The effects of probiotic supplementation on renal function, inflammation, and oxidative stress in diabetic nephropathy: a systematic review and meta-analysis of randomized controlled trials","volume":"11","author":"Wang","year":"2021","journal-title":"Mater Express."},{"key":"B246","doi-asserted-by":"publisher","first-page":"4763","DOI":"10.1039\/C8FO00888D","article-title":"Metabolic and genetic response to probiotics supplementation in patients with diabetic nephropathy: a randomized, double-blind, placebo-controlled trial","volume":"9","author":"Mafi","year":"2018","journal-title":"Food Funct."},{"key":"B247","doi-asserted-by":"publisher","first-page":"CD013631","DOI":"10.1002\/14651858.CD013631.pub2","article-title":"Synbiotics, prebiotics and probiotics for people with chronic kidney disease","volume":"10","author":"Cooper","year":"2023","journal-title":"Cochrane Database Syst Rev."},{"key":"B248","doi-asserted-by":"publisher","first-page":"1385872","DOI":"10.3389\/fendo.2024.1385872","article-title":"Effects of dietary intervention on diabetic nephropathy: an umbrella review of systematic reviews and meta-analyses of randomized controlled trials","volume":"15","author":"Cai","year":"2024","journal-title":"Front Endocrinol."},{"key":"B249","doi-asserted-by":"publisher","first-page":"908219","DOI":"10.3389\/fimmu.2022.908219","article-title":"The specific alteration of gut microbiota in diabetic kidney diseases-a systematic review and meta-analysis","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol."},{"key":"B250","doi-asserted-by":"publisher","first-page":"20220909","DOI":"10.1515\/biol-2022-0909","article-title":"Analysis of the microecological mechanism of diabetic kidney disease based on the theory of \u201cgut-kidney axis\u201d: a systematic review","volume":"19","author":"Huang","year":"2024","journal-title":"Open Life Sci."},{"key":"B251","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1002\/sctm.19-0419","article-title":"A systematic review and meta-analysis of cell-based interventions in experimental diabetic kidney disease","volume":"10","author":"Hickson","year":"2021","journal-title":"Stem Cells Transl Med."},{"key":"B252","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13287-020-02108-5","article-title":"Administration of mesenchymal stem cells in diabetic kidney disease: a systematic review and meta-analysis","volume":"12","author":"Lin","year":"2021","journal-title":"Stem Cell Res Ther."},{"key":"B253","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1681\/ASN.0000000000000189","article-title":"Safety and preliminary efficacy of mesenchymal stromal cell (ORBCEL-M) therapy in diabetic kidney disease: a randomized clinical trial (NEPHSTROM)","volume":"34","author":"Perico","year":"2023","journal-title":"J Am Soc Nephrol."},{"key":"B254","doi-asserted-by":"publisher","first-page":"8833725","DOI":"10.1155\/2020\/8833725","article-title":"Mesenchymal stem cell therapy for diabetic kidney disease: a review of the studies using syngeneic, autologous, allogeneic, and xenogeneic cells","volume":"2020","author":"S\u00e1vio-Silva","year":"2020","journal-title":"Stem Cells Int."},{"key":"B255","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.3390\/ijms22041546","article-title":"Therapeutic potential of mesenchymal stem cells in a pre-clinical model of diabetic kidney disease and obesity","volume":"22","author":"S\u00e1vio-Silva","year":"2021","journal-title":"Int J Mol Sci."},{"key":"B256","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s00109-024-02432-w","article-title":"The therapeutic effect of mesenchymal stem cells in diabetic kidney disease","volume":"102","author":"Habiba","year":"2024","journal-title":"J Mol Med Berl Ger."},{"key":"B257","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1093\/stmcls\/sxad010","article-title":"Mesenchymal stem cell-derived exosomes ameliorate diabetic kidney disease through the NLRP3 signaling pathway","volume":"41","author":"Wang","year":"2023","journal-title":"Stem Cells."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1631053\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T05:27:50Z","timestamp":1754630870000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1631053\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,8]]},"references-count":257,"alternative-id":["10.3389\/fmed.2025.1631053"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1631053","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,8]]},"article-number":"1631053"}}